Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pacira Pharmaceuticals (PCRX) PT Lowered to $66 at BMO Capital
August 5, 2021 12:41 PM EDTBMO Capital analyst Gary Nachman lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $66.00 (from $70.00) while maintaining a Market Perform rating.
The analyst commented, "Exparel had solid 2Q (preannounced 7/13), and PCRX is optimistic strong momentum should continue in 2H21 with... More
